Background: Even if detected at an early stage, a substantial number of lung cancers relapse after curative surgery.
introduction
The adoption of low-dose helical computed tomography (CT) screening is expected to increase the rate of detection of earlystage lung cancer [1, 2] . In fact, 51.8% of lung cancers detected by positive low-dose helical CT screening in the National Lung Screening trial were reportedly at stage IA [3] . However, early detection does not always guarantee cure of the disease. A significant number of early-stage lung cancers paradoxically relapse even after complete surgical resection of the primary tumor and pathological confirmation of absence of any regional lymph node metastasis. In our registry study, for example the 5-year survival rate of patients with stage IA lung cancer failed to reach 80% [4] , indicating that a small proportion of lung cancers acquire a highly metastatic phenotype even from an early stage and are associated with clinically undetectable micrometastases. As the common form of relapse after locally curative surgery is distant metastasis, the use of adjuvant chemotherapy has been considered to improve the outcome of these early-stage lung cancers. However, the majority of patients with early-stage disease are cured by surgery alone. Therefore, it seems necessary to select patients who have a high risk of disease recurrence in order to provide tailored therapy.
Actinin-4 is an actin-binding protein, which we originally identified as showing increased expression in cells with enhanced motility [5] . Actinin-4 directly regulates cell motility through remodeling of the actin cytoskeleton [5, 6] . During the process of cell movement, the expression level of actinin-4 protein is markedly increased, and the protein is concentrated at the leading edge of motile cells [5] . Knockdown of actinin-4 suppresses the migration and invasiveness of cancer cells [7] [8] [9] [10] . Conversely, its overexpression in mice increases cell motility and causes lymph node metastasis [6] . The expression of actinin-4 protein is closely associated with a poor outcome in patients with cancers of the breast [5] , colorectum [6] , pancreas [8, 11] , and ovary [12] . Using unbiased array-based gene expression analysis, Yamagata et al. [13] have found that a small proportion of NSCLCs express a high level of actinin-4 mRNA. Patients with these NSCLCs reportedly showed markedly shorter overall survival. However, the sample size in that study was small, and follow-up was terminated at 2 years. Therefore, the significance of their findings remains to be verified.
Oncogenes are activated by various forms of genomic alteration, including mutation, rearrangement, and gene amplification. Gene amplification is often associated with aggressive behavior of cancers. Breast cancer with CERBB2/ HER2 gene amplification was considered to be the most aggressive until the introduction of trastuzumab (Herceptin) [14] . Amplification of MYCN is an established predictor of poor outcome in patients with neuroblastoma [15] . The ACTN4 gene encoding actinin-4 is frequently amplified in invasive ductal carcinoma of the pancreas and advanced (stages III and IV) ovarian cancer, and well correlated with poor prognosis [8, 16] .
Here, we report that ACTN4 gene amplification can identify a distinct subset of patients with stage I lung adenocarcinoma for whom the outcome will be extremely unfavorable even after complete resection of their tumors. Adenocarcinoma is one of the major histological subtypes of NSCLC and recognized to have a distinct genetic background and clinical behavior [17] . We have also developed a practical method of detecting such patients using a combination of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) on routine formalin-fixed paraffin-embedded pathology tissue sections with the intention of translating the present findings into clinical use.
materials and methods

patient samples
We used archival tissue samples from one training (supplementary Table S1 , available at Annals of Oncology online) and three validation (supplementary Table S2 , available at Annals of Oncology online) cohorts totaling 1744 patients who underwent surgical resection of histologically proven primarily lung adenocarcinoma at two National Cancer Center (NCC)-affiliated hospitals (the Central and East Hospitals). The protocol of this study was reviewed and approved by the institutional ethics board of the NCC.
The cases examined in this study are summarized as follows: We constructed tissue microarrays (TMA) from 543 pathological stage I-IV lung adenocarcinomas and analyzed them using FISH. Amplification of the ACTN4 gene was detected in 79 (15%) of these cases (supplementary Figure S1E , available at Annals of Oncology online). The frequency of gene amplification was significantly higher in smokers (P = 0.018, χ 2 test), and in cancers at an advanced pathological stage (P = 0.0017) or showing poor histological differentiation (P = 0.0017), but there was no significant correlation with sex, age, or EGFR and KRAS mutation (Table 1) .
prognostic significance of ACTN4 gene amplification
We observed that ACTN4 gene amplification was significantly correlated with poor outcome in the 543 patients with lung adenocarcinoma at all stages (4.58 × 10
, log-rank test) ( Figure 1A ). The hazard ratio for death in FISH-positive cases relative to negative cases was 2.65 [95% confidence interval (CI) 1.76-3.98, P = 3.07 × 10
, univariate Cox regression analysis] (supplementary Table S3 , available at Annals of Oncology online). However, the prognostic impact of ACTN4 gene amplification was more evident among patients with stage I lung adenocarcinoma (hazard ratio for death in FISH-positive cases relative to negative cases, 10.53; 95% CI 4.15-26.7; P = 7.14 × 10 −7 ) ( Table 2) . Twenty-three FISH-positive cases were found to have had an outcome significantly worse than that for the 267 negative cases [P = 1.70 × 10 −10 and P = 6.99 × 10 −15 for overall survival and disease-free survival (DFS), respectively, log-rank test] ( Figure 1B and C) . Multivariate analysis revealed that ACTN4 gene amplification (P = 9.48 × 10 , Cox regression analysis) was the most significant independent risk factor for death, followed by age (P = 0.013) and pathological stage (stage IA versus IB) (P = 0.033) ( Table 2) .
Subgroup analysis of patients with stage IA or IB disease revealed similar levels of significance (supplementary Figure S2 , available at Annals of Oncology online). More importantly, Figure S3 , available at Annals of Oncology online).
validation in an independent cohort
The prognostic significance of ACTN4 gene amplification was then tested in another patient cohort for validation. Methanolfixed paraffin-embedded tissue sections [18] were available for 206 stage I cases in Cohort 1. Kaplan-Meier analysis revealed that 20 FISH-positive cases showed a significantly poorer outcome than 186 negative cases (P = 4.00 × 10
, log-rank test) ( Figure 1D ), being consistent with the aforementioned results of TMA.
actinin-4 protein expression
Increased protein expression is one of the main consequences of gene amplification and directly compromises the proper regulation of gene function. We next examined the prognostic impact of actinin-4 protein expression. Because of tissue heterogeneity, the small core size of TMA was not suitable for evaluating the expression of actinin-4 protein, and therefore, the expression of actinin-4 protein was evaluated immunohistochemically using conventional tissue sections from 540 lung adenocarcinomas (Cohort 1, pathological stages I-III). Actinin-4 protein expression was positive in 302 (56%) cases and negative in 238 (44%). Actinin-4 protein was localized in the cell membrane and cytoplasm of cancer cells spreading along the alveolar septum and infiltrating into the fibrotic stroma (supplementary Figure S4A , available at Annals of Oncology online).
IHC-positive cases had a significantly worse outcome than IHC-negative cases (supplementary Figure S4B , available at Annals of Oncology online). The 5-year overall survival rate for patients with IHC-positive cancers was estimated to be 69%, whereas that for patients with IHC-negative cancers was 82% (P = 1.96 × 10 −4 for overall survival, log-rank test). The prognostic impact of actinin-4 protein expression was also evident among stage I cases (P = 6.34 × 10 −3 for overall survival, log-rank test) (supplementary Figure S4C , available at Annals of Oncology online). IHC-positive cases showed a significantly worse outcome than negative cases (hazard ratio for death in IHC-positive cases relative to IHC-negative cases, 2.11; 95% CI 1.22-3.67; P = 7.65 × 10 , univariate Cox regression analysis).
development of a practical method for detection of ACTN4 gene amplification
Although the overall discrimination capability of FISH seems to be superior to that of IHC, FISH is a rather complex procedure that requires experienced technical staff, and thus may not be cost-and labor-effective in routine oncological practice. Therefore, it seems to be more realistic to first identify IHC-positive cases and then examine those cases with FISH, a practical combination that is already widely accepted for evaluating the Her2 status of breast cancer [19] , than to examine all cases with FISH. To evaluate the feasibility of this combination, we compared the FISH and IHC data for 206 cases of stage I lung adenocarcinomas in Cohort 1. Among 107 IHC-positive cases, 19 (18%) were shown to be positive by FISH, whereas among 99 IHCnegative cases only 1 (1%) was FISH-positive. The difference in the proportion of positivity was statistically significant (P < 0.001, Fisher's exact test). The presence of IHC-positive and FISH-negative cases indicates that gene amplification is not solely responsible for an increased level of actinin-4 protein expression. However, the rarity of FISH-positive cases among IHC-negative cases supports the feasibility of the combination. IHC-positive and FISH-positive cases showed a significantly worse outcome than IHC-positive and FISH-negative cases or IHC-negative cases (P = 3.47 × 10 −3 and P = 3.48 × 10
, respectively, for overall survival, log-rank test) (Figure 2A) . It was noteworthy that 75 (97%) of 77 patients with IHC-negative and FISH-negative stage IA cancers were estimated to survive for more than 5 years. 
validation of the test combination in independent cohorts
We then examined the discrimination capability of the IHC and FISH combination by applying it to independent validation cohorts of stage I lung adenocarcinoma resected at two National Cancer Center (NCC)-affiliated hospitals [Cohorts 2 (214 cases resected at the NCC Central Hospital) and Cohort 3 (447 cases resected at the NCC East Hospital)]. Consistent with the result for Cohort 1, IHC-positive and FISH-positive stage I cases showed distinctly worse overall survival than IHC-positive and FISH-negative or IHC-negative cases ( Figure 2B and C).
discussion
The efficacy of platinum-based postsurgical adjuvant chemotherapy for patients with advanced NSCLC has been established through several clinical trials [20] [21] [22] [23] . However, the indication of adjuvant chemotherapy for early-stage NSCLC still remains controversial. In the Adjuvant Navelbine International Trialist Association (ANITA) trial [22] , survival benefit was observed among patients with stage II NSCLC, but not among those with stage IB disease. Another randomized trial revealed a significant benefit of uracil-tegafur for patients with stage IB lung adenocarcinoma [24] , but not those with stage IA disease. In the GALGB 9633 trial, only stage IB NSCLC patients with tumors larger than 4 cm benefited from adjuvant chemotherapy with paclitaxel and carboplatin [25] . Based on these reports, the Cancer Care Ontario and American Society of Clinical Oncology Joint Panel decided not to recommend routine adjuvant therapy for stage I NSCLC [20] . These conflicting results indicate that the current TNM staging system is not sufficient for discriminating patients who would likely experience recurrence after complete surgical resection and thus benefit from postsurgical adjuvant chemotherapy.
In the present study, we revealed that amplification of a single metastasis-related gene was able to identify a small but substantial subset of stage I lung adenocarcinomas with a markedly unfavorable outcome, and its degree of discrimination exceeded that of the current standard TNM staging. However, actinin-4 might be useful not only for prognostic stratification of patients with stage I lung adenocarcinoma, but also for identifying patients who are likely to benefit from postsurgical adjuvant therapy. The outcome of patients with FISH-positive stage I lung adenocarcinoma in the present study ( Figure 1B ) was almost equivalent to that reported for patients with stage II or IIIA lung cancer [4, 20] . This small subset [8-16% (supplementary Table S1 and S2, available at Annals of Oncology online)] of FISH-positive cases would probably require postsurgical management that differs from that of other stage I cases.
Although this was a retrospective study, the involvement of any analytical bias is unlikely. None of the patients with stage I lung adenocarcinoma had received preoperative neoadjuvant therapy, and postsurgical management was conducted irrespectively of actinin-4 status. All the patients underwent standard surgical operations with curative intent. The NCC Central (Cohorts 1 and 2) and East (Cohort 3) Hospitals are Six cases for whom KRAS mutation data were not available were excluded.
situated in different geographical areas (urban and rural, respectively) and operated independently by different surgical and medical teams. Consistency across the two hospitals indicates the high reproducibility of the present findings. However, it would be ideal to conduct a prospective randomized study to clarify the benefits of tailored adjuvant chemotherapy for patients with stage I lung adenocarcinoma after stratifying them on the basis of ACTN4 gene copy number.
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